Accord Healthcare has received the first positive opinion recommending granting a pan-European marketing authorization for a generic version of Bayer’s Xarelto (rivaroxaban) from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Typically, the European Commission acts to convert CHMP recommendations into formal approvals within 67 days.




